Antisense Technology

'Switching' of Key Gene Demonstrated

Published in Cancer Weekly, November 22nd, 1999

In the November 1, 1999, issue of Nature Biotechnology, scientists from Isis Pharmaceuticals, Carlsbad, California, published results from a study that could lead to the development of new drugs to treat cancer and drugs that could enhance current chemotherapy treatments.

Isis scientists successfully used an antisense oligonucleotide to both increase and decrease the levels of two functionally antagonistic proteins encoded by the Bcl-x gene, one of which is involved in the development of resistance in human tumors to chemotherapeutic agents used to treat cancer. Isis's antisense drugs exploiting this newly found mechanism and inhibiting Bcl-x have the potential to be...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry